Novo Nordisk secures biotech partner for Parkinson's cell therapy as GSK signs hepatitis B drug deal in China
read at Endpoints ↗DealNeutral
Novo Nordisk has found a biotech partner to advance its early‑stage Parkinson's disease cell therapy, giving the program a new development home.
GSK disclosed a commercial agreement to sell its hepatitis B drug in the Chinese market, expanding its presence in that region.
The briefing also mentioned label expansions for two rare‑disease drugs and reported that Genmab has halted a Phase 1 cancer trial.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China”
read at Endpoints ↗85 words · retrieved May 11
comments(0)
5-min edit window · permanent after that